Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors

Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors

BackgroundAlthough immune checkpoint inhibitors (ICIs) generally show poor therapeutic efficacy in patients with epidermal growth factor receptor (EGFR) mutations, certain research indicate that a small proportion of these patients do respond to ICIs. The present study sought to identify the feature...

Full description

Bibliographic Details
Main Authors: Qian Chen, Xiaoling Shang, Ni Liu, Xinchun Ma, Wenfei Han, Xiuwen Wang, Yanguo Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Immunology
Subjects:
non-small cell lung cancer
EGFR mutation
immune checkpoint inhibitors
PD-L1 expression
treatment paradigm
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.931718/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.931718/full

Similar Items